CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Devdatt Kurdikar

President, Chief Executive Officer & Director, Embecta

Search every verified Devdatt Kurdikar interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Devdatt Kurdikar, president and CEO of Embecta, discussed the company’s recent performance and strategy in media appearances. In May 2024, he said Embecta was pleased with its second-quarter earnings, citing strong results across the board. He noted that the company, which became independent from Becton Dickinson about two years ago, had focused on separation and organizational setup. Kurdikar addressed the impact of GLP-1 drugs on the business, stating that Embecta’s U.S. business remained stable from 2017 through fiscal 2023 despite the growth of weekly GLP-1s. He also described Embecta as a drug delivery company, highlighting its manufacturing of about 8 billion injection devices annually for over 100 countries, and said emerging markets would likely remain an injection device market in the near to midterm. Kurdikar also discussed capital allocation and product development. He said the company’s leverage ratio was 3.8 and that it aimed to reduce it to at least three over time, balancing debt paydown with investments for growth. He mentioned that Embecta had a patch pump under FDA review and that the company was actively exploring adding products to its portfolio, including through internal development, M&A, or commercial partnerships, leveraging its strengths in high-volume manufacturing and distribution. In an April 2023 podcast, he discussed efforts to reduce needle discomfort through thinner needles while maintaining manufacturing quality and preventing bending during injection.

Recent appearances

  • Embecta (EMBC) CEO on Diabetes Treatment Market

    May 17, 2024 · 📺 Schwab Network

    Embecta (EMBC) CEO Dev Kurdikar joins Oliver Renick to give an overview of the company and discuss its 2Q earnings. He also talks about the impact of GLP-1 drugs. He then goes over the diabetes treatment market, as well as other emerging markets. Tune in to find out more about the stock market today. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-... Download the Amazon Fire Tv App - https://www.amazon.com/TD-Am…

    Watch on YouTube ↗

  • BD spinoff Embecta looks to build on 100 years of diabetes technology

    April 04, 2023 · 📺 Diabetes Connections

    This week… one of the oldest diabetes companies is looking ahead – Once part of BD, makers of needles and syringes, Embecta is now working on new technology like a patch pump. I’m talking to CEO Dev Kurdikar about moving the company forward, while still serving the patient community that relies on their established technology. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify L…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →